Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Imagion Biosystems Ltd. ( (AU:IBX) ) just unveiled an announcement.
Imagion Biosystems has issued 1.4 million fully paid ordinary shares at a deemed price of 2.2 cents each following the vesting of performance rights granted to Executive Chairman Robert Proulx, and has lodged a cleansing notice under Section 708A of the Corporations Act to confirm the shares were issued without a disclosure document and that the company remains compliant with its continuous disclosure and reporting obligations. The board also reiterated that, consistent with prior disclosures, the Phase 2 clinical trial Investigational New Drug submission for its HER2+ program is expected to be filed with the US Food and Drug Administration in the near term, signalling progress in its clinical development pipeline alongside modest equity issuance to management.
The most recent analyst rating on (AU:IBX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Imagion Biosystems Ltd. stock, see the AU:IBX Stock Forecast page.
More about Imagion Biosystems Ltd.
Imagion Biosystems Limited is an Australian medical technology company developing non-radioactive, precision diagnostic molecular imaging solutions. Leveraging its proprietary MagSense® technology, which combines biotechnology and nanotechnology, the company focuses on enabling earlier and more specific detection of cancer and other diseases than current imaging methods, with a particular emphasis on oncology applications.
Average Trading Volume: 3,879,403
Technical Sentiment Signal: Hold
Current Market Cap: A$12.64M
Learn more about IBX stock on TipRanks’ Stock Analysis page.